Vulvar Cancer Vaccines
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against vulvar cancer and guarantee the finest results for our customers all over the world.
Vulvar Cancer
Vulvar cancer is a malignant, invasive growth in the vulva or the outer portion of the female genitals. The labia majora are the most common site involved representing about 50% of all cases, followed by the labia minora. The clitoris and Bartholin glands may rarely be involved. Vulvar cancer is separate from vulvar intraepithelial neoplasia (VIN), a superficial lesion of the epithelium that has not invaded the basement membrane—or a pre-cancer. VIN may progress to carcinoma-in-situ and, eventually, squamous cell cancer. The disease accounts for only 0.6% of cancer diagnoses but 5% of gynecologic cancers in the United States.
There has been a striking increase in the incidence of VIN and vulvar carcinoma over the past 30 years, especially in younger women. The observed increase in younger women could be due to a higher incidence of infection of the lower genital tract with human papillomavirus or it may be explained by better diagnostic procedures or both.
Preventative HPV Vaccines for Vulvar Cancer
Human papilloma virus (HPV) is a double stranded DNA virus and it is transmitted by direct contact of the skin and mucous membranes. More than 100 human types of HPV have been identified and ~40 HPV types infect the skin and mucous membranes of the anogenital region. HPV are divided into low- and high-risk types according to their ability to induce premalignant and malignant transformation. Vulvar carcinoma can be HPV-positive or HPV-negative. More than 40% of vulvar cancers are associated with HPV and the association is higher in younger women. HPV–positive tumors tend to be nonkeratinizing basaloid or warty tumors, often surrounded by Bowenoid-type vulvar intraepithelial neoplasia. Human papillomavirus 16 is the most frequently observed virus in vulvar cancer. HPV–positive vulvar cancer, which are associated with younger patients, have been diagnosed more frequently in recent decades and are thought to have a better prognosis than the HPV-negative tumors. HPV–negative vulvar cancers are more frequently found in older women, often with a history of nonneoplastic epithelial disorders of the vulvar skin, such as lichen sclerosis. Vaccination against HPV can reduce the risk of vulvar cancers. More HPV vaccines for vulvar cancer are being developed and tested.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the HPV vaccine development against the vulvar cancer. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
